MARCELLUSI, ANDREA
MARCELLUSI, ANDREA
Dipartimento di Scienze Farmaceutiche
Oxygen-Enriched Olive-Oil Dressing in Moderate-Degree Pediatric Burns: Impact on Care and Budget over a 4-Year Period in a Tertiary Children’s Hospital
2026 S. Borghetti, U.M. Pierucci, C. Palladino, S. Vimercati, F. Selmin, A. Marcellusi, G. Tosi, A. Musitelli, E. Zoia, I. Paraboschi, G. Pelizzo
Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025-2027
2025 A. Marcellusi, D. Cazzato, G. Guarnotta, A. Aiello, M. Bonfanti, R. Bitonti, M. Guardigni, C. Lucchetti, F. Luccini, P. Canonico, C. Jommi
Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control
2025 M. Paoletti, A. Ragonese, L. Budassi, A. Marcellusi
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
2025 J. Lazarus, L. Agirre-Garrido, L. Díaz, P. Danpanichkul, S. Kivuyo, L. Kondili, H. Hagström, H. Takahashi, J. Pericàs, C. Spearman, C. Oliveira, C. Villela-Nogueira, J. Schattenberg, E. Toresson Grip, N. Alkhouri, A. Marcellusi, H. Mark, A. Allen, N. Carvalho Leite, H. Al-Omar, S. Alqahtani, N. Brachowicz
Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants.
2025 C. Bini, A. Marcellusi, D. Cazzato, B. Muzii, S. Soudani, E. Bozzola, F. Midulla, E. Baraldi, P. Bonanni, S. Boccalini, L. Orfeo
Pivotal Studies for Drugs About to Be Launched for Rare Diseases: Will They Better Support Health Technology Assessment and Market Access than in the Past?
2025 C. Jommi, M. Bonfanti, M. Guardigni, A. Aiello, A. Marcellusi, P. Canonico, F. Luccini, C. Lucchetti
Burden of disease of Alzheimer disease in Italy: a real-world data analysis
2025 F. Mennini, P. Sciattella, M. Scortichini, R. Migliorini, M. Trabucco Aurilio, A. Marcellusi, A. Bianchetti
Cost-Estimation Model of Prevented Recurrences with Atezolizumab in Early Non-Small-Cell Lung Cancer in Italy
2025 A. Marcellusi, M. Belfiore, R. Tempre, M. Buonfiglio, A. Russo
Long-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy
2025 F. Mennini, P. Sciattella, C. Simonelli, A. Marcellusi, S. Rosato, L. Kondili
Evoluzione terapeutica: tradurre l'innovazione farmacologica in benefici tangibili per le persone con emofilia A. Una prospettiva multi-stakeholder
2025 M.N.D. Di Minno, V. Drago, A. Marcellusi, S. Amato, C. Mattia, E.F. Grazzi, F. Drago, D. Fornasari
The economic benefit of implementing assisted reproductive technology within a national health system: insights from the Italian model
2025 A. Marcellusi, M. Scortichini, G. Guarnotta, M. Connolly, A. Busnelli
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy.
2025 M. Paoletti, A. Marcellusi, D. Di Laura, R. Van Den Puttelaar, G. Van De Wetering, M. Jootun
Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
2025 A. Marcellusi, C. Bini, B. Muzii, S. Soudani, A. Kieffer, M. Beuvelet, E. Bozzola, F. Midulla, E. Baraldi, P. Bonanni, S. Boccalini, L. Orfeo
Analisi di costo-efficacia di Brentuximab Vedotin + CHP in pazienti con linfoma anaplastico a grandi cellule sistemico [Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy
2025 A. Marcellusi, C. Bini, L. Fioravanti, S. Ripoli, P. Morelli
Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis.
2025 F. Mennini, A. Marcellusi, P. Sciattella, M. Scortichini, A. Ragonese, F. Cattel, R. D'Antona, L. Del Mastro, S. Gori, G. Perrone, R. Migliorini, M. Trabucco Aurilio
The economic burden of asthma in Italy: evaluating the potential impact of different treatments in adult patients with severe eosinophilic asthma
2024 M. Scortichini, F. Mennini, A. Marcellusi, M. Paoletti, C. Tomino, P. Sciattella
Impatto economico di dapagliflozin nella gestione della malattia renale cronica in Italia: risultati di un modello di micro-simulazione. = Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation model
2024 R. Ravasio, A. Marcellusi, L. De Nicola
High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma
2024 J. Pöhlmann, M. Weller, A. Marcellusi, K. Grabe-Heyne, L. Krott-Coi, S. Rabar, R. Pollock
An Analysis of the Distribution of Direct Cost of Diabetes Care in Selected Districts in Italy
2024 F. Mennini, P. Sciattella, A. Marcellusi, F. Bartolini, F. Bernardi, F. Levrat-Guillen, M. Cozzolino, M. Di Gennaro, R. Giordana, M. Giustozzi, U. Trama
Analisi di costo-efficacia di brentuximab vedotin in combinazione con doxorubicina, vinblastina e dacarbazina (AVD) in pazienti adulti affetti da linfoma di Hodgkin in stadio IV.
2024 A. Marcellusi, C. Bini, F. Saverio Mennini, S. Ripoli, L. Fioravanti, V. Federico Paly, A. Lina Molinari, P. Morelli, S. Krotneva, S. Li